Skip to main content

EDAP TMS SA

corporate_fare Company Profile

EDAP TMS SA

EDAP TMS S.A., together with its subsidiaries, develops, manufactures, promotes, and distributes minimally-invasive medical devices for urology based upon proprietary ultrasound technology in Asia, France, the United States, and internationally. The company operates through High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution segments. The HIFU segment develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications. This segment also offers Focal One, a HIFU robotic system to treat patients diagnosed with prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL segment manufactures and markets lithotripter for the treatment of urinary tract stones; and provides disposables, replacement parts, and services for lithotripters. This segment also sells spare parts and disposables, such as electrodes. The Distribution segment markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. It markets and sells its products through its direct marketing and sales channels, as well as through third-party distributors and agents. The company serves academic, public, and private hospitals as well as urology clinics. EDAP TMS S.A. was incorporated in 1979 and is based in Vaulx-en-Velin, France.

Exchange: NASDAQSector: Industrial Applications And Services

EDAP TMS SA (NASDAQ:EDAP) is a publicly traded company in the Industrial Applications And Services sector. Wiseek monitors EDAP SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • EDAP TMS Files Definitive Proxy Materials Detailing Increased FY2025 Losses and Going Concern Warning for Annual Meeting
  • EDAP TMS Seeks Shareholder Approval for Highly Dilutive Capital Raise and Debt Authorization Amid Going Concern Warning
  • EDAP TMS SA Reports Strong Q1 HIFU Growth, Secures €12M EIB Tranche B to Address Liquidity
  • EDAP TMS Reports Record Q1 HIFU Revenue Growth, Reaffirming 2026 Guidance
  • Shareholders to Vote on Authorizing Over 60% Potential Share Dilution for Financing and Operations

show_chartPrice Chart

Loading chart...

feed EDAP - Latest Insights

EDAP
May 14, 2026, 7:32 AM EDT
Filing Type: DEFA14A
Importance Score:
8
EDAP
May 14, 2026, 7:30 AM EDT
Filing Type: DEF 14A
Importance Score:
9
EDAP
May 07, 2026, 4:03 PM EDT
Filing Type: 10-Q
Importance Score:
8
EDAP
May 07, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
8
EDAP
May 01, 2026, 4:01 PM EDT
Filing Type: PRE 14A
Importance Score:
9
EDAP
Apr 30, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
9
EDAP
Apr 02, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
EDAP
Mar 25, 2026, 4:25 PM EDT
Filing Type: S-3
Importance Score:
9
EDAP
Mar 25, 2026, 4:25 PM EDT
Source: Wiseek News
Importance Score:
8
EDAP
Mar 25, 2026, 4:15 PM EDT
Filing Type: 10-K
Importance Score:
9
EDAP
Mar 25, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
7
EDAP
Feb 12, 2026, 7:30 AM EST
Filing Type: 8-K
Importance Score:
7
EDAP
Jan 12, 2026, 7:30 AM EST
Filing Type: 8-K
Importance Score:
8